BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
Keyword: Dapagliflozin
1
Role of sodium-glucose co-transporter 2 inhibitors in liver diseases
12/19/2025 8:32:37 AM | Browse: 34 | Download: 129
2
Dapagliflozin as an oral antihyperglycemic agent in the management of diabetes mellitus in patients with liver cirrhosis
10/31/2024 7:40:50 AM | Browse: 126 | Download: 683
3
Advancing cardiovascular outcomes with dapagliflozin and sacubitril in post-acute myocardial infarction heart failure and type 2 diabetes mellitus
10/31/2024 7:21:20 AM | Browse: 127 | Download: 664
4
Effect of dapagliflozin on uric acid in patients with chronic heart failure and hyperuricemia
6/18/2024 9:29:50 AM | Browse: 146 | Download: 834
5
Comparative efficacy of sodium glucose cotransporter-2 inhibitors in the management of type 2 diabetes mellitus: A real-world experience
3/15/2024 9:49:53 AM | Browse: 174 | Download: 768
6
Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis
11/24/2022 8:01:57 AM | Browse: 569 | Download: 1394
7
Functional annotation and enrichment analysis of differentially expressed serum proteins in patients with type 2 diabetes after dapagliflozin
3/15/2022 2:23:07 PM | Browse: 621 | Download: 1720
8
Cardiovascular benefits from SGLT2 inhibition in type 2 diabetes mellitus patients is not impaired with phosphate flux related to pharmacotherapy
12/23/2021 6:10:00 AM | Browse: 562 | Download: 996
9
Role of sodium-glucose co-transporter-2 inhibitors in the management of heart failure in patients with diabetes mellitus
5/11/2020 9:58:04 AM | Browse: 953 | Download: 1858
Write to the Help Desk
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345